Salix Pharmaceuticals (SLXP) 172.96 $SLXP
McEldrew Young Whistleblower Lawsuit Against Valeant Subsidiary Salix Settles For $54 Million
PR Newswire - Thu Jun 09, 3:15PM CDT
McEldrew Young, Attorneys-at-Law, announces a $54 million dollar settlement of its False Claims Act qui tam lawsuit against Salix Pharmaceuticals, a subsidiary of Valeant Pharmaceuticals, by the United States Department of Justice ("DOJ"
. Salix knowingly caused the submission of false claims to Medicare and Medicaid by paying kickbacks to prescribing physicians, including sham "speaking" fees, according to the allegations in the lawsuit In re Salix, Case No. 12-3870, in the United States District Court for the Southern District of New York.
SLXP: 172.96 (+0.15)
Salix Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 10:46AM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
SLXP: 172.96 (+0.15)
RedHill Biopharma Announces Appointment of Rick D. Scruggs to Board of Directors
GlobeNewswire - Tue Dec 15, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company" , an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced the appointment of Mr. Rick D. Scruggs to its Board of Directors, effective January 1, 2016.
RDHL: 14.89 (-0.08), SLXP: 172.96 (+0.15)
BioDelivery Sciences Hires Joseph M. Lockhart as Vice President of Manufacturing and Supply Chain
PR Newswire - Thu Dec 03, 6:00AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) appointed Joseph (Jody) M. Lockhart as Vice President of Manufacturing and Supply Chain. In this role, Mr. Lockhart will be responsible for overseeing all manufacturing-related activities for both BDSI's currently approved products, including the currently marketed product BUNAVAIL® (buprenorphine and naloxone) buccal film as well as ONSOLIS (fentanyl buccal soluble film), which was reacquired from Meda Pharmaceuticals earlier this year. Mr. Lockhart will also be responsible for scale up and manufacturing activities for BDSI's development pipeline. Mr. Lockhart will report to Dr. Mark A. Sirgo, President and Chief Executive Officer.
BDSI: 2.39 (-0.05), SLXP: 172.96 (+0.15)
Irritable Bowel Syndrome Global Clinical Trials Review Report, H1, 2015
M2 - Wed Nov 11, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxkgsx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015 provides data on the Irritable Bowel Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Irritable Bowel Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - GlaxoSmithKline plc - Novartis AG - Actavis plc - Astellas Pharma Inc. - Salix Pharmaceuticals Ltd. - Ironwood Pharmaceuticals, Inc. - AstraZeneca PLC - Ono Pharmaceutical Co., Ltd. - Almirall, S.A. - A. Menarini Industrie Farmaceutiche Riunite Srl Clinical Trial Overview of Top Institutes / Government - Mayo Clinic - University of North Carolina - University of Nottingham - Maastricht University Medical Center - Sahlgrenska University Hospital - Chinese University of Hong Kong - Cedars-Sinai Medical Center - Karolinska Institute - University of California, Los Angeles - Baylor College of Medicine For more information visit http://www.researchandmarkets.com/research/vx...able_bowel
IRWD: 13.25 (-0.09), AZN: 32.64 (-0.17), SLXP: 172.96 (+0.15), GSK: 42.98 (-0.48), NVS: 78.22 (-0.55)
Salix Pharmaceuticals Partnering 2010-2015 - Reportlinker Review
PR Newswire - Wed Nov 04, 11:47AM CST
The Partnering Agreements with Salix Pharmaceuticals 2010-2015 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.
SLXP: 172.96 (+0.15)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 305.65 (+0.02), UTHR: 122.55 (+0.27), CTIC: 0.39 (unch), CHRS: 29.90 (+0.13), JNJ: 118.87 (-0.47), NPSP: 45.97 (+0.01), IBIO: 0.63 (+0.02), EBS: 26.28 (-0.37), SLXP: 172.96 (+0.15), AMGN: 169.66 (-0.40), SPPI: 5.26 (-0.05), LLY: 77.13 (-0.62), GSK: 42.98 (-0.48), ANIK: 47.90 (+0.66), NVO: 46.30 (-0.42), BAX: 46.12 (-0.61), MRK: 62.69 (-0.10), NVS: 78.22 (-0.55)
FDA Grants RUCONEST® (C1 Esterase Inhibitor [Recombinant]) Twelve-Year Reference Product Exclusivity
PR Newswire - Thu Oct 08, 6:00AM CDT
Salix Pharmaceuticals and Pharming Group NV (EURONEXT: PHARM) announced today that the U.S. Food and Drug Administration (FDA) has granted 12 years of exclusivity to RUCONEST® (C1 esterase inhibitor [recombinant]) 50 IU/kg. The determination of exclusivity ensures that FDA will not approve before July 16, 2026 any applications for biosimilars of RUCONEST-- i.e. applications for recombinant C1 esterase inhibitors referencing RUCONEST submitted under section 351(k) of the Public Health Service Act under the framework established by the Biologics Price Competition and Innovation Act of 2009.
VRX: 29.03 (unch), SLXP: 172.96 (+0.15), VRX.TO: 38.01 (-0.08)
Rheumatoid Arthritis - Pipeline Review, H1 2015
M2 - Fri Aug 21, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/263t2k/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - AB Science - Baliopharm - Bio-Cancer Treatment International - Can-Fite BioPharma - Cardax Pharmaceuticals - Daiichi Sankyo Company - Dong-A Socio - Effimune - F. Hoffmann-La Roche - Farmacija d.o.o. Tuzla - GeneFrontier - Handok - Hanmi Pharmaceuticals - Idera Pharmaceuticals - Johnson & Johnson - Kadmon Corporation - Lead Pharma - Mabion - MacroGenics - Navigen Pharmaceuticals - Neovacs - Oncobiologics - Padlock Therapeutics - Qu Biologics - R-Pharm - Salix Pharmaceuticals - Takeda Pharmaceutical - TechnoPhage - Vaccinex - Vertex Pharmaceuticals Incorporated - XBiotech USA - Yuhan Corporation - Yungjin Pharm Ind. - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/263t2k/rheumatoid
CANF: 2.45 (-0.03), JNJ: 118.87 (-0.47), VRTX: 94.39 (-0.12), IDRA: 1.88 (-0.03), SLXP: 172.96 (+0.15)
Life Cycle Management Strategies - Optimizing Revenues and Defending Generic Competition
M2 - Tue Aug 18, 9:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55nhrh/life_cycle) has announced the addition of the "Life Cycle Management Strategies - Optimizing Revenues and Defending Generic Competition" report to their offering. This report, ""Life Cycle Management Strategies - Optimizing revenues and defending generic competition"" discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on. Scope of the report: - Introduction of LCM and product life cycle - Objectives of LCM and factors impacting the choice of strategies - LCM strategies depending on the way of approach - Impact of LCM strategies on sales and growth trend of selected products - Patent term extension and market exclusivity in the US and Europe - LCM strategies of pipeline drugs of key players - Keys to successful implementation of LCM strategies Key Reasons to Purchase: - Identify the key LCM strategies used by most of the pharmaceutical companies - Analyze the strategies to increase lifecycle and revenues of a drug - Gain an understanding on the implementation of multiple strategies for a single product by including case studies - Understand the operational pipeline strategies of key players Key Topics Covered: 1. Executive Summary 2. Introduction 2.1 Overview of Product Life Cycle 2.2 Product Life Cycle Curve 2.3 Objectives of Life Cycle Management (LCM) 2.4 Classification and Benefits of LCM Strategies 3. Strategic Planning for LCM 3.1 Factors Impacting Choice of LCM Strategies 3.2 Developmental Strategies 3.3 Indication Expansion/Sequencing and Repositioning 3.4 Patient Subpopulations and Personalized Medicine 3.5 Reformulation 3.6 New Dosage Forms 3.7 New Route of Administration 3.8 Special Cases 4. New Dosage Strengths and Regimen 4.1 Fixed-Dose Combination and Co-packaging 4.2 Next Generation Products and Modified Chemistry 4.3 Metabolites 4.4 Chiral Switching 4.5 Polymorphs 4.6 Multiple Developmental Strategy Approach 5. Commercial Strategies 5.1 Rx-to-OTC/BTC Switch 5.2 Geographical Expansion 5.3 Pricing Strategy and Tactics 5.4 Pricing Strategy for Targeting Multiple Indications 5.5 Coupons 5.6 Co-pay Cards 5.7 Awareness, Brand Loyalty and Service Programs 6. Regulatory and Legal Strategies 6.1 Authorized Generics 6.2 Legal Defense and Pay for Delay 6.3 Citizen's Petition 6.4 Patent Term Extension and Market Exclusivity 6.5 The Pharmaceutical Pipeline and LCM 6.6 Successful Implementation of LCM Strategies 7. Appendix Companies Mentioned - AbbVie - Actavis - AstraZeneca - Cipla - Gilead - GlaxoSmithKline - Gleevec - Janssen - MannKind - Merck - Novartis - Orexo - Otsuka - Pfizer - Roche - Salix Pharmaceuticals - Sanofi-Aventis - Solvay - Teva - Vifor Pharma For more information visit http://www.researchandmarkets.com/research/55nhrh/life_cycle About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 62.68 (-0.11), SLXP: 172.96 (+0.15), GSK: 42.98 (-0.48), NVS: 78.22 (-0.55)
Global Congestive Heart Failure (Heart Failure) API Insights 2015-2016
M2 - Mon Aug 17, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fjv4tz/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure)-API Insights" report to their offering. Congestive Heart Failure (Heart Failure) API Insights, 2015 report provides Congestive Heart Failure (Heart Failure) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Congestive Heart Failure (Heart Failure). The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Congestive Heart Failure (Heart Failure) drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Companies Mentioned - AstraZeneca Pharmaceuticals, LP - Biovail Laboratories International SRL - AstraZeneca PLC - Merck & Co., Inc. - Novartis Pharmaceuticals Corporation - Pfizer Inc. - Bristol-Myers Squibb Company - Salix Pharmaceuticals Ltd. - Roxane Laboratories, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline LLC - Par Pharmaceutical Companies, Inc. - Sanofi - Paddock Laboratories, Inc. - Scios Inc. - Arbor Pharmaceuticals, Inc. - Biovail Pharmaceuticals, Inc. - Aton Pharma, Inc. - GlaxoSmithKline plc - Baxter Healthcare Corporation - Hospira, Inc. - Bayer AG - AbbVie Inc. - Pohl Boskamp - Abbott Laboratories - Procter & Gamble Pharmaceuticals, Inc. - Dr. Reddy's Laboratories Limited For more information visit http://www.researchandmarkets.com/research/fj...tive_heart
ABT: 42.13 (+0.11), PFE: 34.66 (-0.14), MRK: 62.68 (-0.11), AZN: 32.64 (-0.17), SLXP: 172.96 (+0.15), ABBV: 63.79 (-0.31), PG: 88.26 (+0.95), GSK: 42.98 (-0.48), BMY: 56.77 (-0.62), NVS: 78.22 (-0.55)
RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals
GlobeNewswire - Mon Jul 27, 6:00AM CDT
-- Salix Pharmaceuticals, recently acquired by Valeant Pharmaceuticals, confirmed to RedHill that it continues the development of RedHill's RHB-106 encapsulated bowel preparation
VRX: 29.03 (unch), RDHL: 14.89 (-0.08), SLXP: 172.96 (+0.15), VRX.TO: 38.01 (-0.08)
Global Inflammatory Bowel Disease Market 2015-2019 - Dominance of Market by Biologics
M2 - Tue Jul 21, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhn6mx/global) has announced the addition of the "Global Inflammatory Bowel Disease Market 2015-2019" report to their offering. This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis. The dominance of the market by biologics used to treat patients suffering from the disease is one of the emerging trends. Biologics are expected to become a preferred treatment option for the medical fraternity, patients, and the families of patients during the forecast period. This leads to a rise in the number of treatment-seeking patients, which increases the overall consumption of medicines. According to the report, the high prevalence of inflammatory bowel disease among the population resulting in a rise in the number of treatment-seeking patients has led to increased consumption of medications, thereby having a positive impact on the market share of the vendors. Further, the report states the high cost of drugs used to treat patients suffering from inflammatory bowel disease is one of the major challenges hindering the growth of the market. On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments. - 5-ASA - Antibiotics - Immunomodulators On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Biologics - Small Molecules On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Oral - Parenteral On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments. - Solid - Liquid Key Vendors - Abbvie - Biogen Idec - Janssen Pharmaceuticals - Merck & Company - Shire - UCB Other Prominent Vendors - Amgen - Akebia Therapeutics - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Galapagos - Genentech - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Salix Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vhn6mx/global
BIIB: 305.65 (+0.02), NVO: 46.30 (-0.42), MRK: 62.68 (-0.11), SLXP: 172.96 (+0.15), AMGN: 169.66 (-0.40), AKBA: 8.06 (-0.07), NVS: 78.22 (-0.55)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights 2015-2016
M2 - Fri Jul 10, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6zxdj/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease)-API Insights" report to their offering. Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights, 2015 report provides Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Reflux Esophagitis (Gastroesophageal Reflux Disease). The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Scope - A snapshot of the global Market therapeutics scenario for Renal Stones/Calculi. - A review of the marketed products under prescription for Renal Stones/Calculi, regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Renal Stones/Calculi with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Renal Stones/Calculi drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Renal Stones/Calculi drugs. - Key discontinued Marketed products. - Global Sales Figure from 2012-2016. Companies Mentioned - Salix Pharmaceuticals Ltd. - Santarus, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline Inc. - AstraZeneca PLC - Hanmi USA, Inc. - Braintree Laboratories, Inc. - SmithKline Beecham PLC - GlaxoSmithKline plc - AstraZeneca Pharmaceuticals, LP - Takeda Pharmaceuticals U.S.A., Inc. - UCB, Inc. - Pfizer Inc. - ANI Pharmaceuticals, Inc. - American Home Products Corporation - Alaven Pharmaceutical LLC (Inactive) - Teva Pharmaceutical Industries Limited - Merck & Co., Inc. - Eisai Inc. - Perrigo Company For more information visit http://www.researchandmarkets.com/research/q6zxdj/reflux
SNTS: (), PRGO: 90.51 (-0.48), ANIP: 61.08 (+1.34), PFE: 34.66 (-0.14), MRK: 62.68 (-0.11), AZN: 32.64 (-0.17), SLXP: 172.96 (+0.15), TEVA: 51.10 (+0.71), GSK: 42.97 (-0.49)
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 54.0% (SLXP)
Comtex SmarTrend(R) - Mon Jul 06, 9:10AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on December 17th, 2014 at $112.23. In approximately 7 months, Salix Pharmaceuticals has returned 53.99% as of today's recent price of $172.81.
SLXP: 172.96 (+0.15)
Salix Pharmaceuticals Up 54.0% Since SmarTrend Uptrend Call (SLXP)
Comtex SmarTrend(R) - Fri Jun 26, 9:18AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on December 17th, 2014 at $112.23. In approximately 6 months, Salix Pharmaceuticals has returned 53.99% as of today's recent price of $172.81.
SLXP: 172.96 (+0.15)
Shares of SLXP Up 54.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 18, 4:48PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on December 17th, 2014 at $112.23. In approximately 6 months, Salix Pharmaceuticals has returned 53.99% as of today's recent price of $172.81.
SLXP: 172.96 (+0.15)
Salix Pharmaceuticals Shares Up 54.0% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Thu Jun 11, 11:28AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on December 17th, 2014 at $112.23. In approximately 6 months, Salix Pharmaceuticals has returned 53.99% as of today's recent price of $172.81.
SLXP: 172.96 (+0.15)
McEldrew Young Whistleblower Lawsuit Against Valeant Subsidiary Salix Settles For $54 Million
PR Newswire - Thu Jun 09, 3:15PM CDT
McEldrew Young, Attorneys-at-Law, announces a $54 million dollar settlement of its False Claims Act qui tam lawsuit against Salix Pharmaceuticals, a subsidiary of Valeant Pharmaceuticals, by the United States Department of Justice ("DOJ"
. Salix knowingly caused the submission of false claims to Medicare and Medicaid by paying kickbacks to prescribing physicians, including sham "speaking" fees, according to the allegations in the lawsuit In re Salix, Case No. 12-3870, in the United States District Court for the Southern District of New York. SLXP: 172.96 (+0.15)
Salix Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 10:46AM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
SLXP: 172.96 (+0.15)
RedHill Biopharma Announces Appointment of Rick D. Scruggs to Board of Directors
GlobeNewswire - Tue Dec 15, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced the appointment of Mr. Rick D. Scruggs to its Board of Directors, effective January 1, 2016. RDHL: 14.89 (-0.08), SLXP: 172.96 (+0.15)
BioDelivery Sciences Hires Joseph M. Lockhart as Vice President of Manufacturing and Supply Chain
PR Newswire - Thu Dec 03, 6:00AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) appointed Joseph (Jody) M. Lockhart as Vice President of Manufacturing and Supply Chain. In this role, Mr. Lockhart will be responsible for overseeing all manufacturing-related activities for both BDSI's currently approved products, including the currently marketed product BUNAVAIL® (buprenorphine and naloxone) buccal film as well as ONSOLIS (fentanyl buccal soluble film), which was reacquired from Meda Pharmaceuticals earlier this year. Mr. Lockhart will also be responsible for scale up and manufacturing activities for BDSI's development pipeline. Mr. Lockhart will report to Dr. Mark A. Sirgo, President and Chief Executive Officer.
BDSI: 2.39 (-0.05), SLXP: 172.96 (+0.15)
Irritable Bowel Syndrome Global Clinical Trials Review Report, H1, 2015
M2 - Wed Nov 11, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxkgsx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015 provides data on the Irritable Bowel Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Irritable Bowel Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - GlaxoSmithKline plc - Novartis AG - Actavis plc - Astellas Pharma Inc. - Salix Pharmaceuticals Ltd. - Ironwood Pharmaceuticals, Inc. - AstraZeneca PLC - Ono Pharmaceutical Co., Ltd. - Almirall, S.A. - A. Menarini Industrie Farmaceutiche Riunite Srl Clinical Trial Overview of Top Institutes / Government - Mayo Clinic - University of North Carolina - University of Nottingham - Maastricht University Medical Center - Sahlgrenska University Hospital - Chinese University of Hong Kong - Cedars-Sinai Medical Center - Karolinska Institute - University of California, Los Angeles - Baylor College of Medicine For more information visit http://www.researchandmarkets.com/research/vx...able_bowel
IRWD: 13.25 (-0.09), AZN: 32.64 (-0.17), SLXP: 172.96 (+0.15), GSK: 42.98 (-0.48), NVS: 78.22 (-0.55)
Salix Pharmaceuticals Partnering 2010-2015 - Reportlinker Review
PR Newswire - Wed Nov 04, 11:47AM CST
The Partnering Agreements with Salix Pharmaceuticals 2010-2015 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.
SLXP: 172.96 (+0.15)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 305.65 (+0.02), UTHR: 122.55 (+0.27), CTIC: 0.39 (unch), CHRS: 29.90 (+0.13), JNJ: 118.87 (-0.47), NPSP: 45.97 (+0.01), IBIO: 0.63 (+0.02), EBS: 26.28 (-0.37), SLXP: 172.96 (+0.15), AMGN: 169.66 (-0.40), SPPI: 5.26 (-0.05), LLY: 77.13 (-0.62), GSK: 42.98 (-0.48), ANIK: 47.90 (+0.66), NVO: 46.30 (-0.42), BAX: 46.12 (-0.61), MRK: 62.69 (-0.10), NVS: 78.22 (-0.55)
FDA Grants RUCONEST® (C1 Esterase Inhibitor [Recombinant]) Twelve-Year Reference Product Exclusivity
PR Newswire - Thu Oct 08, 6:00AM CDT
Salix Pharmaceuticals and Pharming Group NV (EURONEXT: PHARM) announced today that the U.S. Food and Drug Administration (FDA) has granted 12 years of exclusivity to RUCONEST® (C1 esterase inhibitor [recombinant]) 50 IU/kg. The determination of exclusivity ensures that FDA will not approve before July 16, 2026 any applications for biosimilars of RUCONEST-- i.e. applications for recombinant C1 esterase inhibitors referencing RUCONEST submitted under section 351(k) of the Public Health Service Act under the framework established by the Biologics Price Competition and Innovation Act of 2009.
VRX: 29.03 (unch), SLXP: 172.96 (+0.15), VRX.TO: 38.01 (-0.08)
Rheumatoid Arthritis - Pipeline Review, H1 2015
M2 - Fri Aug 21, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/263t2k/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - AB Science - Baliopharm - Bio-Cancer Treatment International - Can-Fite BioPharma - Cardax Pharmaceuticals - Daiichi Sankyo Company - Dong-A Socio - Effimune - F. Hoffmann-La Roche - Farmacija d.o.o. Tuzla - GeneFrontier - Handok - Hanmi Pharmaceuticals - Idera Pharmaceuticals - Johnson & Johnson - Kadmon Corporation - Lead Pharma - Mabion - MacroGenics - Navigen Pharmaceuticals - Neovacs - Oncobiologics - Padlock Therapeutics - Qu Biologics - R-Pharm - Salix Pharmaceuticals - Takeda Pharmaceutical - TechnoPhage - Vaccinex - Vertex Pharmaceuticals Incorporated - XBiotech USA - Yuhan Corporation - Yungjin Pharm Ind. - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/263t2k/rheumatoid
CANF: 2.45 (-0.03), JNJ: 118.87 (-0.47), VRTX: 94.39 (-0.12), IDRA: 1.88 (-0.03), SLXP: 172.96 (+0.15)
Life Cycle Management Strategies - Optimizing Revenues and Defending Generic Competition
M2 - Tue Aug 18, 9:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55nhrh/life_cycle) has announced the addition of the "Life Cycle Management Strategies - Optimizing Revenues and Defending Generic Competition" report to their offering. This report, ""Life Cycle Management Strategies - Optimizing revenues and defending generic competition"" discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on. Scope of the report: - Introduction of LCM and product life cycle - Objectives of LCM and factors impacting the choice of strategies - LCM strategies depending on the way of approach - Impact of LCM strategies on sales and growth trend of selected products - Patent term extension and market exclusivity in the US and Europe - LCM strategies of pipeline drugs of key players - Keys to successful implementation of LCM strategies Key Reasons to Purchase: - Identify the key LCM strategies used by most of the pharmaceutical companies - Analyze the strategies to increase lifecycle and revenues of a drug - Gain an understanding on the implementation of multiple strategies for a single product by including case studies - Understand the operational pipeline strategies of key players Key Topics Covered: 1. Executive Summary 2. Introduction 2.1 Overview of Product Life Cycle 2.2 Product Life Cycle Curve 2.3 Objectives of Life Cycle Management (LCM) 2.4 Classification and Benefits of LCM Strategies 3. Strategic Planning for LCM 3.1 Factors Impacting Choice of LCM Strategies 3.2 Developmental Strategies 3.3 Indication Expansion/Sequencing and Repositioning 3.4 Patient Subpopulations and Personalized Medicine 3.5 Reformulation 3.6 New Dosage Forms 3.7 New Route of Administration 3.8 Special Cases 4. New Dosage Strengths and Regimen 4.1 Fixed-Dose Combination and Co-packaging 4.2 Next Generation Products and Modified Chemistry 4.3 Metabolites 4.4 Chiral Switching 4.5 Polymorphs 4.6 Multiple Developmental Strategy Approach 5. Commercial Strategies 5.1 Rx-to-OTC/BTC Switch 5.2 Geographical Expansion 5.3 Pricing Strategy and Tactics 5.4 Pricing Strategy for Targeting Multiple Indications 5.5 Coupons 5.6 Co-pay Cards 5.7 Awareness, Brand Loyalty and Service Programs 6. Regulatory and Legal Strategies 6.1 Authorized Generics 6.2 Legal Defense and Pay for Delay 6.3 Citizen's Petition 6.4 Patent Term Extension and Market Exclusivity 6.5 The Pharmaceutical Pipeline and LCM 6.6 Successful Implementation of LCM Strategies 7. Appendix Companies Mentioned - AbbVie - Actavis - AstraZeneca - Cipla - Gilead - GlaxoSmithKline - Gleevec - Janssen - MannKind - Merck - Novartis - Orexo - Otsuka - Pfizer - Roche - Salix Pharmaceuticals - Sanofi-Aventis - Solvay - Teva - Vifor Pharma For more information visit http://www.researchandmarkets.com/research/55nhrh/life_cycle About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 62.68 (-0.11), SLXP: 172.96 (+0.15), GSK: 42.98 (-0.48), NVS: 78.22 (-0.55)
Global Congestive Heart Failure (Heart Failure) API Insights 2015-2016
M2 - Mon Aug 17, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fjv4tz/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure)-API Insights" report to their offering. Congestive Heart Failure (Heart Failure) API Insights, 2015 report provides Congestive Heart Failure (Heart Failure) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Congestive Heart Failure (Heart Failure). The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Congestive Heart Failure (Heart Failure) drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Companies Mentioned - AstraZeneca Pharmaceuticals, LP - Biovail Laboratories International SRL - AstraZeneca PLC - Merck & Co., Inc. - Novartis Pharmaceuticals Corporation - Pfizer Inc. - Bristol-Myers Squibb Company - Salix Pharmaceuticals Ltd. - Roxane Laboratories, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline LLC - Par Pharmaceutical Companies, Inc. - Sanofi - Paddock Laboratories, Inc. - Scios Inc. - Arbor Pharmaceuticals, Inc. - Biovail Pharmaceuticals, Inc. - Aton Pharma, Inc. - GlaxoSmithKline plc - Baxter Healthcare Corporation - Hospira, Inc. - Bayer AG - AbbVie Inc. - Pohl Boskamp - Abbott Laboratories - Procter & Gamble Pharmaceuticals, Inc. - Dr. Reddy's Laboratories Limited For more information visit http://www.researchandmarkets.com/research/fj...tive_heart
ABT: 42.13 (+0.11), PFE: 34.66 (-0.14), MRK: 62.68 (-0.11), AZN: 32.64 (-0.17), SLXP: 172.96 (+0.15), ABBV: 63.79 (-0.31), PG: 88.26 (+0.95), GSK: 42.98 (-0.48), BMY: 56.77 (-0.62), NVS: 78.22 (-0.55)
RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals
GlobeNewswire - Mon Jul 27, 6:00AM CDT
-- Salix Pharmaceuticals, recently acquired by Valeant Pharmaceuticals, confirmed to RedHill that it continues the development of RedHill's RHB-106 encapsulated bowel preparation
VRX: 29.03 (unch), RDHL: 14.89 (-0.08), SLXP: 172.96 (+0.15), VRX.TO: 38.01 (-0.08)
Global Inflammatory Bowel Disease Market 2015-2019 - Dominance of Market by Biologics
M2 - Tue Jul 21, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhn6mx/global) has announced the addition of the "Global Inflammatory Bowel Disease Market 2015-2019" report to their offering. This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis. The dominance of the market by biologics used to treat patients suffering from the disease is one of the emerging trends. Biologics are expected to become a preferred treatment option for the medical fraternity, patients, and the families of patients during the forecast period. This leads to a rise in the number of treatment-seeking patients, which increases the overall consumption of medicines. According to the report, the high prevalence of inflammatory bowel disease among the population resulting in a rise in the number of treatment-seeking patients has led to increased consumption of medications, thereby having a positive impact on the market share of the vendors. Further, the report states the high cost of drugs used to treat patients suffering from inflammatory bowel disease is one of the major challenges hindering the growth of the market. On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments. - 5-ASA - Antibiotics - Immunomodulators On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Biologics - Small Molecules On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Oral - Parenteral On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments. - Solid - Liquid Key Vendors - Abbvie - Biogen Idec - Janssen Pharmaceuticals - Merck & Company - Shire - UCB Other Prominent Vendors - Amgen - Akebia Therapeutics - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Galapagos - Genentech - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Salix Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vhn6mx/global
BIIB: 305.65 (+0.02), NVO: 46.30 (-0.42), MRK: 62.68 (-0.11), SLXP: 172.96 (+0.15), AMGN: 169.66 (-0.40), AKBA: 8.06 (-0.07), NVS: 78.22 (-0.55)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights 2015-2016
M2 - Fri Jul 10, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6zxdj/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease)-API Insights" report to their offering. Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights, 2015 report provides Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Reflux Esophagitis (Gastroesophageal Reflux Disease). The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Scope - A snapshot of the global Market therapeutics scenario for Renal Stones/Calculi. - A review of the marketed products under prescription for Renal Stones/Calculi, regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Renal Stones/Calculi with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Renal Stones/Calculi drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Renal Stones/Calculi drugs. - Key discontinued Marketed products. - Global Sales Figure from 2012-2016. Companies Mentioned - Salix Pharmaceuticals Ltd. - Santarus, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline Inc. - AstraZeneca PLC - Hanmi USA, Inc. - Braintree Laboratories, Inc. - SmithKline Beecham PLC - GlaxoSmithKline plc - AstraZeneca Pharmaceuticals, LP - Takeda Pharmaceuticals U.S.A., Inc. - UCB, Inc. - Pfizer Inc. - ANI Pharmaceuticals, Inc. - American Home Products Corporation - Alaven Pharmaceutical LLC (Inactive) - Teva Pharmaceutical Industries Limited - Merck & Co., Inc. - Eisai Inc. - Perrigo Company For more information visit http://www.researchandmarkets.com/research/q6zxdj/reflux
SNTS: (), PRGO: 90.51 (-0.48), ANIP: 61.08 (+1.34), PFE: 34.66 (-0.14), MRK: 62.68 (-0.11), AZN: 32.64 (-0.17), SLXP: 172.96 (+0.15), TEVA: 51.10 (+0.71), GSK: 42.97 (-0.49)
Uptrend Call Working As Salix Pharmaceuticals Stock Rises 54.0% (SLXP)
Comtex SmarTrend(R) - Mon Jul 06, 9:10AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on December 17th, 2014 at $112.23. In approximately 7 months, Salix Pharmaceuticals has returned 53.99% as of today's recent price of $172.81.
SLXP: 172.96 (+0.15)
Salix Pharmaceuticals Up 54.0% Since SmarTrend Uptrend Call (SLXP)
Comtex SmarTrend(R) - Fri Jun 26, 9:18AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on December 17th, 2014 at $112.23. In approximately 6 months, Salix Pharmaceuticals has returned 53.99% as of today's recent price of $172.81.
SLXP: 172.96 (+0.15)
Shares of SLXP Up 54.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 18, 4:48PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on December 17th, 2014 at $112.23. In approximately 6 months, Salix Pharmaceuticals has returned 53.99% as of today's recent price of $172.81.
SLXP: 172.96 (+0.15)
Salix Pharmaceuticals Shares Up 54.0% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Thu Jun 11, 11:28AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on December 17th, 2014 at $112.23. In approximately 6 months, Salix Pharmaceuticals has returned 53.99% as of today's recent price of $172.81.
SLXP: 172.96 (+0.15)
